Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET)



Status:Recruiting
Conditions:Constipation, Parkinsons Disease
Therapuetic Areas:Gastroenterology, Neurology
Healthy:No
Age Range:30 - 90
Updated:3/31/2019
Start Date:December 10, 2018
End Date:November 2019
Contact:Denise Barbut, MD, FRCP
Email:d.barbut@enterininc.com
Phone:(215) 634-9243

Use our guide to learn which trials are right for you!

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)

This study will be conducted as a multi-center, randomized, double-blind, placebo-controlled
study. Approximately 72 patients will be randomized 3:1 to treatment or placebo, with
approximately 54 patients allocated to receive the active investigational product and
approximately 18 patients allocated to receive placebo.

The study will be conducted on an out-patient basis. Each patient will have 6 visits to the
clinic: a screening visit, a randomization visit, 3 follow up visits, and 1 end of study
visit.

Patient randomization will be stratified based upon the baseline weekly complete spontaneous
bowel movement rate (CSBM) established during the screening period. Patients will be allowed
to adjust their dosing, based upon protocol specifications. Rescue medications will be
provided to all patients to ensure they move their bowels on a regular basis.

Patients will also be asked to participate in up to 2 sub-studies: a pk study and/or a stool
microbiome study. The first 20 patients to consent to the pk study will have additional blood
samples taken at randomization and at 2 follow up visits. The first 10 patients to consent to
the stool microbiome study will provide stool samples at randomization and at 2 follow up
visits.

Inclusion Criteria:

1. Subjects aged 30-90 years, both genders

2. Subjects must provide written informed consent and be willing and able to comply with
study procedures.

3. Subjects must be diagnosed with Parkinson's Disease defined as the presence of at
least three of the following cardinal features, in the absence of alternative
explanations or atypical features: rest tremor, rigidity, bradykinesia and/or
akinesia, postural and gait abnormalities.

4. There are insufficient criteria for Irritable Bowel Syndrome (IBS)

5. Constipation which has been present for over 6 months and is unresponsive to first
line, typically over the counter treatments such as Milk of Magnesia (1g), Miralax
(17g in 8 ounces of water) or the equivalent at least once weekly with an inconsistent
response over a 6-week period or the subject is dissatisfied with first line
treatments.

6. Body mass index (BMI) of 18-40 kg/m2

7. Subjects must fulfill Rome IV criteria for functional constipation which includes 2 or
more of the following:

1. Straining during at least 25% of defecations

2. Lumpy or hard stools in at least 25% of defecations

3. Sensation of incomplete evacuation for at least 25% of defecations

4. Sensation of anorectal obstruction/blockage for at least 25% of defecations

5. Manual maneuvers to facilitate at least 25% of defecations (e.g., digital
evacuation, support of the pelvic floor)

8. Self-report of fewer than 3 complete spontaneous bowel movements per week

9. Loose stools are rarely present without the use of laxatives

10. Subjects must be able to read, understand, and accurately record data into the diary
to guarantee full participation in the study.

11. Female subjects must have negative serum or urine pregnancy tests and must not be
lactating. For females able to bear children, a hormonal (i.e., oral, implantable, or
injectable) and single-barrier method, or a double-barrier method of birth control
must be used throughout the study. A vasectomized partner will be allowed as one in
conjunction with another single-barrier method.

12. Female subjects unable to bear children must have this documented in the CRF (i.e.,
tubal ligation, hysterectomy, or postmenopausal [defined as a minimum of one year
since the last menstrual period]). Post-menopausal status will be confirmed by
follicle stimulating hormone (FSH) in women less than 60 years of age.

Exclusion Criteria:

1. Unable or unwilling to provide informed consent or to comply with study procedures.

2. Diagnosis of secondary constipation beyond that of Parkinson's Disease

3. Review of Screening Diaries indicates fewer than 11 days of diary completion and/or 3
or more complete spontaneous bowel movements (CSBM) per week based upon the average
CSBM rate reported during the Screening Period

4. A compromised gastrointestinal system which includes:

1. Structural, metabolic, or functional GI diseases or disorders

2. Acute GI illness within 2 weeks of the screening visit

3. History of major GI surgery within 30 days of the screening visit (a history of
cholecystectomy, polypectomy, hernia repair or appendicectomy are not
exclusionary as long as they were performed more than 30 days before the
screening visit)

5. Unable or unwilling to withdraw from laxatives, opiates, clonazepam, or any
medications which may cause constipation, 2 weeks prior to the dose adjustment period
and throughout the rest of the study.

6. Unable or unwilling to withdraw from proton pump inhibitors and antacids at the end of
the screening period.

7. Unable or unwilling to withdraw from pimavanserin during the study.

8. Any clinically significant abnormalities on screening laboratories or physical
examination requiring further evaluation or treatment.

9. Neurological disorder other than Parkinson's Disease that in the opinion of the
investigator might interfere with the conduct of the study.

10. On treatment with intra-jejunal dopamine or carbidopa/levodopa (i.e. Duopa).

11. Subjects starting a new Parkinson's Disease medication or modifying an existing
medication within 2 weeks prior to enrollment.

12. Unable to maintain a stable diet regimen.

13. Subjects with a cognitive impairment that preclude them from understanding the
informed consent.

14. Subjects placed under legal guardianship.

15. Females who are pregnant or breastfeeding.

16. History of excessive alcohol use or substance abuse.

17. Participation in an investigational drug trial within the month prior to dosing in the
present study.

18. Any other reason, which, in the opinion of the investigator, would confound proper
interpretation of the study.
We found this trial at
37
sites
Centerville, Ohio 45459
Principal Investigator: Douglas Pugar, MD
Phone: 937-424-3035
?
mi
from
Centerville, OH
Click here to add this to my saved trials
736 E Bullard Ave
Fresno, California 93710
559-437-9700
Principal Investigator: Perminder Bhatia, MD
?
mi
from
Fresno, CA
Click here to add this to my saved trials
4202 E Fowler Ave
Tampa, Florida 33620
(813) 974-2011
Principal Investigator: Robert A. Hauser, MD
Phone: 813-396-0768
University of South Florida The University of South Florida is a high-impact, global research university...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Alexandria, Louisiana 71301
Principal Investigator: Gonzalo Hidalgo, MD
Phone: 608-848-8900
?
mi
from
Alexandria, LA
Click here to add this to my saved trials
Anderson, Indiana 46011
Principal Investigator: Larry Blankenship, MD
Phone: 765-298-2040
?
mi
from
Anderson, IN
Click here to add this to my saved trials
811 Juniper St NE
Atlanta, Georgia 30308
(404) 881-5800
Principal Investigator: Robert Riesenberg, MD
Phone: 404-881-5800
Atlanta Center for Medical Research Welcome to the Atlanta Center for Medical Research, a leader...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Atlantis, Florida 33462
Principal Investigator: Mark Goldstein, MD
Phone: 561-968-2933
?
mi
from
Atlantis, FL
Click here to add this to my saved trials
Baton Rouge, Louisiana 70810
Principal Investigator: Gerald Calegan, MD
Phone: 225-761-2569
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Bedford, Texas 76201
Principal Investigator: Madhavi Thomas, MD
Phone: 214-437-8579
?
mi
from
Bedford, TX
Click here to add this to my saved trials
Boca Raton, Florida 33486
Principal Investigator: Stuart H Isaacson, MD
Phone: 561-392-1818
?
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Dallas, Texas 75218
Principal Investigator: Sharisse Stephenson, MD
Phone: 214-324-9301
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Dayton, Ohio 45459
Principal Investigator: Joel Vandersluis, MD
Phone: 208-346-8900
?
mi
from
Dayton, OH
Click here to add this to my saved trials
Elkridge, Maryland 21075
Principal Investigator: Stephen Grill, MD
Phone: 443-755-0030
?
mi
from
Elkridge, MD
Click here to add this to my saved trials
Fairfield, Connecticut 06824
Principal Investigator: Srinath Kadimi, MD
Phone: 203-333-1151
?
mi
from
Fairfield, CT
Click here to add this to my saved trials
Fountain Valley, California 92708
Principal Investigator: Daniel D. Truong, MD
Phone: 714-378-5033
?
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Greer, South Carolina 29650
Principal Investigator: Mary D Hughes, MD
Phone: 864-516-1092
?
mi
from
Greer, SC
Click here to add this to my saved trials
Hershey, Pennsylvania 17033
Principal Investigator: Thyagarajan Subramanian, MD
Phone: 717-425-0419
?
mi
from
Hershey, PA
Click here to add this to my saved trials
Houston, Texas 77074
Principal Investigator: Djamchid Lotfi, MD
Phone: 713-484-6947
?
mi
from
Houston, TX
Click here to add this to my saved trials
Indian Land, South Carolina 29707
Principal Investigator: Howard Mandell, MD
Phone: 608-848-8900
?
mi
from
Indian Land, SC
Click here to add this to my saved trials
Las Vegas, Nevada 89128
Principal Investigator: Shanker Dixit, MD
Phone: 702-425-1798
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Lincoln, Nebraska 68506
Principal Investigator: Gary Pattee, MD
Phone: 402-486-3430
?
mi
from
Lincoln, NE
Click here to add this to my saved trials
Little Rock, Arkansas 72205
Principal Investigator: Victor Biton, MD
Phone: 501-227-6179
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Miami, Florida 33145
Principal Investigator: Gretel Trullenque, MD
?
mi
from
Miami, FL
Click here to add this to my saved trials
Miami, Florida 33155
Principal Investigator: Michael Pfeffer, MD
Phone: 225-287-4276
?
mi
from
Miami, FL
Click here to add this to my saved trials
Miami, Florida 33175
Principal Investigator: Otto Marquez-Mendoza, MD
Phone: 786-953-7630
?
mi
from
Miami, FL
Click here to add this to my saved trials
Norfolk, Virginia 23456
Principal Investigator: Karen M Thomas, DO
Phone: 757-507-0642
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
Norwich, Connecticut 06360
Principal Investigator: Anis Racy, MD
Phone: 860-886-1508
?
mi
from
Norwich, CT
Click here to add this to my saved trials
Oxnard, California
Principal Investigator: James Sutton, MD
Phone: 805-278-4148
?
mi
from
Oxnard, CA
Click here to add this to my saved trials
3390 Tamiami Trail
Port Charlotte, Florida 33952
Principal Investigator: George Li, MD
Phone: 941-623-9744
?
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
Raleigh, North Carolina 27607
Principal Investigator: Bradley Robottom, MD
?
mi
from
Raleigh, NC
Click here to add this to my saved trials
Santa Clarita, California 91321
Principal Investigator: Surisham Dhillon, MD
Phone: 908-941-2273
?
mi
from
Santa Clarita, CA
Click here to add this to my saved trials
1700 S Tamiami Trail
Sarasota, Florida 34239
(941) 917-9000
Principal Investigator: Dean Sutherland, MD, PhD
Phone: 941-917-6164
Sarasota Memorial Hospital Sarasota Memorial Health Care System, an 806-bed regional medical center, is among...
?
mi
from
Sarasota, FL
Click here to add this to my saved trials
Sun City, Arizona 85351
Principal Investigator: David Shprecher, DO
Phone: 623-832-5706
?
mi
from
Sun City, AZ
Click here to add this to my saved trials
Toms River, New Jersey 08755
Principal Investigator: Rocco DiPaola, MD
Phone: 732-341-9500
?
mi
from
Toms River, NJ
Click here to add this to my saved trials
Tulsa, Oklahoma 74136
Principal Investigator: Kevin Klos, MD
Phone: 918-392-4530
?
mi
from
Tulsa, OK
Click here to add this to my saved trials
Wake Forest, North Carolina 27157
Principal Investigator: Jessica Tate, MD
Phone: 336-716-8694
?
mi
from
Wake Forest, NC
Click here to add this to my saved trials
West Bloomfield, Michigan 48322
Principal Investigator: Peter Lewitt, MD
Phone: 248-661-7257
?
mi
from
West Bloomfield, MI
Click here to add this to my saved trials